Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Urinary Bladder Neoplasms 4Sarcoma, Alveolar Soft Part 3Carcinoma, Transitional Cell 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Urethral Neoplasms 2Ureteral Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Glioblastoma 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2Extensive Stage Lung Small Cell Carcinoma 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Clear Cell 1Sarcoma 1Rhabdoid Tumor 1Recurrent Bladder Urothelial Carcinoma 1Papillary renal cell carcinoma, sporadic 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Mesothelioma, Malignant 1

Interventions

X-Rays 7Phantoms, Imaging 7Magnetic Resonance Spectroscopy 7Specimen Handling 6Nuclear Medicine Department, Hospital 5Temozolomide 4Biopsy 4ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2Vorinostat 2Vemurafenib 2LY3023414 2Carboplatin 2veliparib 1cediranib 1atezolizumab 1Vincristine 1Tiragolumab 1Thiotepa 1Radiotherapy 1Pharmacogenomic Variants 1Peripheral Blood Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Rhabdoid Tumor × atezolizumab × Clear all
NCT05286801 2026-05-13

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
86 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡